PharmaShots Weekly Snapshots (May 20 – May 24, 2024)

Share this

PharmaShots Weekly Snapshots (May 20 – May 24, 2024)

This week PharmaShots’ news was all about the updates on M&A, Pharma, Clinical Trials, Regulatory & MedTech. Check out our full report below:


Endeavor BioMedicines Reports Results from the P-IIa Study of ENV-101 for Treating Idiopathic Pulmonary Fibrosis

Read More: Endeavor BioMedicines                                                                         

Vicore Highlights the P-IIa (AIR) Study Data of Buloxibutid for the Treatment of Idiopathic Pulmonary Fibrosis at ATS 2024

Read More: Vicore                                                                                                         

GSK Reports Results from the P-III (SWIFT-1 and SWIFT-2) Studies of Depemokimab for Treating Severe Asthma

Read More: GSK                                                                                                      

Sanofi Highlights Data from the P-III (NOTUS) Study of Dupixent for COPD at ATS 2024 and Publishes in the NEJM

Read More: Sanofi                                                                                                      

Sanofi Highlights Data from P-II Trial of Rilzabrutinib to Treat Moderate-to-Severe Asthma at ATS 2024

Read More: Sanofi                                                                                                          

Eupraxia Pharmaceuticals Reports EP-104GI’s P-Ib/2a (RESOLVE) Study Expansion to Treat Eosinophilic Esophagitis (EoE)

Read More: Eupraxia Pharmaceuticals                                                                   

Laekna’s LAE002(Afuresertib) + LAE001 Receives FDA Approval for P-III Trial Protocol to Treat Prostate Cancer

Read More: Laekna                                                                                                     

IRLAB Initiates Dosing with IRL757 in the P-I Study for Apathy

Read More: IRLAB                 

HI-Bio Presents Positive Interim Data from P-II (IGNAZ) Trial of Felzartamab for IgA at 61st ERA Congress 2024

Read More: HI-Bio                                                                                  


Zai Lab and Innoviva Specialty Therapeutics Reports the NMPA’s Approval of Xacduro (sulbactam-durlobactam) for Hospital-Acquired and Ventilator-Associated Pneumonia

Read More: Zai Lab & Innoviva                                                                                

The USPTO Issues Notice of Allowance for New Patent Covering MediciNova’s Ibudilast (MN-166) to Prevent Metastasis of Eye Cancer

Read More: MediciNova                                                                                         

Roche’s Inavolisib Receives the US FDA’s Breakthrough Therapy Designation for Breast Cancer

Read More: Roche                                                                                                    

Innovent Reports the NMPA’s NDA Acceptance of IBI311 for Treating Thyroid Eye Disease

Read More: Innovent                                                                                              

BMS Reports the US FDA’s Updated Action Date for Subcutaneous Opdivo (Nivolumab and Hyaluronidase)

Read More: BMS                                                                                                      

Aktis Oncology and Eli Lilly Collaborate to Discover and Develop Novel Anticancer Radiopharmaceuticals

Read More: Aktis Oncology & Eli Lilly                                                                   

Cartesian Therapeutics’ Descartes-08 Gains the US FDA’s RMAT Designation to Treat Myasthenia Gravis

Read More: Cartesian Therapeutics                                                                      

The US FDA Grants Fast Track Designation to Theriva Biologics’ VCN-01 as 1L Treatment of PDAC

Read More: Theriva Biologics                                                                                   

Shanghai Henlius and Organon Got EMA’s Validation for the MAA of HLX14 (Biosimilar, Prolia & Xgeva)

Read More: Shanghai Henlius & Organon                                                   


Boston Scientific Corporation Highlights 6 Months Data of MODULAR ATP Study & 5 Years Data of APPRAISE ATP Study at Heart Rhythm 2024

Read More: Boston Scientific                                                                                    

Roche’s Blood Test to Measure Lp(a) Receives the US FDA’s Breakthrough Device Designation, Enhancing its Cardiovascular Portfolio

Read More: Roche                                                                                         

The US FDA Clears Indica Labs’ HALO AP Dx Digital Pathology Platform

Read More: Indica Labs                                                                                          


Fractyl Health Highlights the Preclinical Data of its Pancreatic Gene Therapy at DDW 2024

Read More: Fractyl Health                                                                                        


Biocon’s Yesafili (Biosimilar, Eylea) Receives the US FDA’s Approval for Ophthalmology

Read More: Biocon                                                                                                     

Sandoz Reports EC’s Approval of Wyost and Jubbonti (Biosimilars, Xgeva and Prolia)

Read More: Sandoz                                                                                                    


Boehringer Ingelheim and OSE Immunotherapeutics Expand Partnership to Develop Therapies for Cancer and Cardio-Renal-Metabolic (CRM) Diseases

Read More: Boehringer Ingelheim & OSE Immunotherapeutics                      

Cytokinetics Expands its Funding Collaboration with Royalty Pharma to Commercialize Aficamten and Advance R&D Pipeline

Read More: Cytokinetics & Royalty Pharma                                                        


Swixx Biopharma Acquires Biopas, Expanding its Presence to Latin America

Read More: Swixx Biopharma & Biopas                                                              

For an Aggregate of $1.8B, Biogen Acquires Human Immunology Biosciences to Strengthen its Immunology Portfolio

Read More: Biogen & Human Immunology Biosciences                                   

Merck KGaA Reports the Acquisition of Mirus Bio, Strengthening Upstream Portfolio

Read More: Merck KGaA & Mirus Bio                                                                   

Orna Therapeutics Acquires ReNAgade for Circular RNA Therapies

Read More: Orna Therapeutics & ReNAgade                       

Related Post: PharmaShots Weekly Snapshots (May 13 – May 17, 2024)            

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions